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The  immune  system  plays  a key  role  in  health  maintenance  and pathogenesis  of  a wide  range  of  diseases.
Leukocytes  that  are present  in the  blood  convey  valuable  information  about  the  status  of  the  immune
system.  Blood  transcriptomics,  which  consists  in  proﬁling  blood  transcript  abundance  on genome-wide
scales,  has  gained  in  popularity  over  the  past  several  years.  Indeed,  practicality  and  simplicity  largely
makes  up  for what  this  approach  may  lack  in  terms  of cell  population-level  resolution.  An  extensive
survey  of  the literature  reveals  increasingly  widespread  use  across  virtually  all ﬁelds  of medicine  as  well
as across  a number  of  different  animal  species,  including  model  organisms  but  also  animals  of  economical
importance.  Dissemination  across  such  a  wide  range  of disciplines  holds  the promise  of adding  a  new
perspective,  breadth  or context,  to the  considerable  depth  afforded  by  whole  genome  proﬁling  of  blood
transcript  abundance.  Indeed,  it is  only through  such  contextualization  that a  truly  global  perspective
will  be gained  from  the  use of  systems  approaches.  Also  discussed  are  opportunities  that  may  arise  for
the  ﬁelds  of immunology  and  medicine  from  using  blood  transcriptomics  as  a  common  denominator  for
developing  interactions  and  cooperation  across  ﬁelds  of  research  that  have  traditionally  been and  largely
remain  compartmentalized.  Finally,  an  argument  is  made  for  building  immunology  research  capacity
using  blood  transcriptomics  platforms  in  low-resource  and  high-disease  burden  settings.
© 2015  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license. Introduction to systems approaches
The use of systems approaches is transforming the biomedical
esearch landscape by enabling the comprehensive molecular pro-
ling of cells and tissues obtained from human subjects in health
nd disease. Systems approaches leverage high throughput tech-
ologies to measure all the parameters that can be measured in
 given biological system (often referred to as “omics” technolo-
ies). Indeed, as a result, and in contrast with the more “traditional”
ssays, investigators do not need to choose the parameters that
ill be measured as it will by default simply be “everything”,
nd it is in that sense that these approaches are inherently unbi-
sed. Genomics is probably the most popular omics approach
nd has beneﬁted from swift technological advances that allow
easurements of constitutive elements of a system on a genome-
ide scale in a single assay (sequence, transcript abundance,
ethylation sites, transcription binding sites, etc). Transcriptome
roﬁling constitutes a genomic approach since it consists in
∗ Correspondence to: Sidra Medical and Research Center, Al Nasr Tower, AL Cor-
iche Street, Qatar Foundation, PO Box 26999, Doha, Qatar. Tel.: +974 4012 5844.
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ttp://dx.doi.org/10.1016/j.smim.2015.03.002
044-5323/© 2015 Published by Elsevier Ltd. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/4.0/).
measuring transcript abundance in a sample on a genome-wide
scale, and relies on detection or sequencing of oligonucleotide
sequences that are present in a sample. Other Omics approaches
rely on technologies that tend to be more costly and challeng-
ing to implement (e.g. proteomics) or that rely on a multiplicity
of assays (e.g. metabolomics) [1]. Indeed a wide range of molecu-
lar proﬁling platforms are available to immunologists, that despite
having not yet truly reached system levels, allow for molecular
and cellular proﬁles on increasingly large scales – (for instance
multiplex protein proﬁling or multi-parameter ﬂow cytometry)
[2,3]. Systems Immunology encompasses the use of such systems
or large-scale approaches in the context of immunological studies.
Indeed interdependence exists amongst elements within a given
system but also across elements constitutive of the different sys-
tems (e.g. between genome sequences, transcriptomes, proteomes,
microbiomes as well as cellular proﬁles). Thus it is more and
more common for immunological studies to incorporate multi-
ple systems-scale or large-scale proﬁling approaches [4,5]. Notably,
while genomic proﬁling capabilities have been available for the past
15 years, technology platforms have continued to gain in sophis-
tication – while, inevitably, analytic pipelines have concurrently
gained in complexity. And each time a new study is imple-
mented the abundance, complexity and heterogeneity of the data it
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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roduces increases in comparison with the previous study. Taken
ogether the data thus being generated has become referred to as
iomedical “Big Data”, with investigators indeed having increas-
ngly to contend with Big Data’s canonical 3 Vs, which stand for
olume (scale), Variety (heterogeneity) and Velocity (speed at
hich the data can be accessed and interrogated). Indeed captur-
ng, storing and integrating all of this data within a given study,
nd especially across studies – i.e. collective biomedical Big Data
 will challenge even the most advanced information technology
olutions within well-resourced research organizations.
. Adding breadth to the depth of systems-scale
nvestigations
This review will focus on only one of several systems or
arge-scale proﬁling approaches available as part of the sys-
ems immunology armamentarium: blood transcriptome proﬁling.
ther articles in this issue cover the use of transcriptome proﬁl-
ng in isolated immune cell populations. Here I will examine the
se of blood transcriptomics technology, an approach that consists
n measuring abundance of RNA in peripheral blood leukocytes,
ononuclear cells or in unfractionated blood on a genome-wide
cale. In particular I will argue that among available systems
mmunology approaches blood transcriptomics is very uniquely
ositioned in that it can add considerable breadth in addition to
he depth that is inherent of systems approaches. By this I mean
hat while, as pointed out above, increased sophistication as well
s “stacking” of technologies is ever increasing proﬁling depth,
readth – context – is at least as critical, if not more, for the
nterpretation of such vast datasets. Context is something that
an be gained by capturing molecular proﬁles on a systems scale
cross a wide array of conditions (treatments, diseases, genetic
nd environmental factors, etc). Indeed, it is only when such a
road scope is attained that the perspective afforded by systems
pproaches becomes truly global. It is then for instance possible
o determine if the activation of a given transcriptional program
s speciﬁc to a disease or common to any number of diseases; the
ame can be said of a novel vaccine adjuvant, since data obtained
rom the proﬁling of approved vaccines or candidate adjuvants will
llow the contextualization of the interpretation of a newly gen-
rated dataset. As will be discussed below it is also breadth and
ontext that allows the identiﬁcation of co-dependencies among
he constituents of the system and the development of molecu-
ar repertoires (see also [6]). Also in my  experience the answer to
ata overload is often simply.  . . more data. Context can be pur-
osely built into a study that will be designed to proﬁle samples
cquired across a vast range of conditions, or it can be gained a
osteriori through the reuse of public domain data – given that
recautions have been taken to ensure that the data is compara-
le. Indeed usable contextual data would be best obtained through
oordination of efforts across research groups and disciplines, and
ore arguments going in that sense will be made below. In addi-
ion to depth and breadth a third complementary dimension, time,
lso contributes to potentiate systems proﬁling approaches espe-
ially when studies that are conducted involve research subjects.
ndeed, adding this perspective accounts for the considerable inter-
ndividual variability by measuring molecular as well as phenotypic
uctuations relative to a ﬁxed point in time from the same indi-
idual. This is the last, but not the least, of the three dimensions
hat in my  opinion can enable effective harnessing of systems
cale proﬁling technologies but it will not be discussed in detail
ere.
So what characteristics make whole blood transcriptomics stand
ut in comparison to other systems proﬁling approaches as far
s data contextualization is concerned? Blood is a tissue. Cellularunology 27 (2015) 58–66 59
heterogeneity is a limitation since changes in transcript abundance
can be associated to either transcriptional regulation or relative
changes in the abundance of different cell populations. Mining
strategies such as in silico deconvolution that account for changes
in cellular composition can mitigate this factor but it does not alto-
gether remove this constraint on the interpretation of the data [7,8].
Nevertheless from the standpoint of the discovery and develop-
ment of biomarker signatures only the performance of the test truly
matters, and this is regardless of whether the change measured
are due to transcriptional modulation or changes in cellular com-
position. It should also be noted that changes in cell composition
that are detected via blood transcript proﬁling can be challeng-
ing to measure, even using methodologies such as ﬂow cytometry.
For instance neutrophil signatures do not correlate with neutrophil
counts but with the presence of immature low-density neutrophil
populations mobilized from the bone marrow [9]. We  also observed
via proﬁling of the blood transcriptome following vaccine admin-
istration a signature associated with an increase in abundance of
antibody producing cells which are very fragile (especially to freez-
ing) and require relatively sophisticated cellular proﬁling via ﬂow
cytometry for quantitation [10]. Indeed, accessibility and robust-
ness of sample acquisition and processing methodologies makes up
for what blood transcriptomics lacks in terms of granularity. Since
blood is a homogeneous tissue no bias is introduced through samp-
ling, which is in contrast with solid organs or tumors since cellular
composition can vary considerably depending on the area where
the sample is obtained. Evacuated blood collection tubes have been
developed that contains a solution disrupting cells and precipitat-
ing RNA immediately upon homogenization by shaking [11,12]. The
collection tubes can then be stored frozen at −20 ◦C indeﬁnitely
without further processing. The robustness of this sample collec-
tion method makes the approach amenable to collection on large
scales and in particularly challenging settings. It also means that
independent sample collections emanating from different studies
could be consolidated for acquisition of transcript proﬁling data a
posteriori. Notably, it is also possible to adapt the methodology for
serial sampling using small volumes of blood, which adds a tem-
poral perspective to the depth and breadth of blood transcriptome
proﬁling studies. And thus it is the simplicity of this sampling and
RNA proﬁle stabilization method that makes whole blood trans-
criptome studies stand out among available systems approaches.
Indeed, blood transcriptomics can be employed as a unifying theme
or common denominator for bridging traditional research silos and
provide in addition to depth contextual as well as temporal per-
spectives.
3. A global survey of the blood transcriptomics literature
I reviewed in 2010 the use of blood transcriptome proﬁling in
immunology studies and the present article provides an update and
fresh perspective on the current state of blood transcriptome inves-
tigations [2]. More recent reviews have focused on speciﬁc subject
areas such as autoimmunity [13,14], Cancer [15], Stroke [16], the
detection of erythropoietin gene doping [17], epilepsy prediction
[18], and Alzheimer’s disease [19].
Here a broader perspective was  gained by conducting an exten-
sive survey of the literature. This allowed for the mapping of the
current landscape of blood transcriptome proﬁling studies. The
evolution of this landscape over time was also examined. The ﬁrst
step consisted in building the following PubMed query to capture
most relevant studies:(blood OR PBMC OR PBMCs OR leukocyte OR leukocytes) AND (“sys-
tems approach” OR “systems immunology” OR transcriptome OR
Transcriptomic OR “gene expression proﬁling” OR “transcriptional
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proﬁling” OR microarray OR microarrays OR RNA-seq OR RNAseq OR
“RNA seq” OR “RNA sequencing”)
This query returned 19,947 articles; but only a fraction of these
ere actually associated with blood transcriptomic studies. Second,
he search was restricted in order to identify studies that either per-
ained to diseases or conditions (e.g. sepsis, rheumatoid arthritis,
utism) or species (e.g. rat, pig, dog). In order to accomplish this
he operator “AND” was used followed by an ad hoc string (e.g. for
epsis: AND (sepsis OR septic OR septicemia OR septiceamia); for
igs: AND (pig OR pigs OR porcine OR swine OR hog OR hogs OR sow
R sows). In some cases where queries returned thousands of sam-
les search for some of the terms were restricted to the title ﬁeld
using the [ti] ﬁeld operator). Next, the query results were curated
anually to identify studies that employed blood transcriptome
roﬁling. Review articles were excluded as were studies employ-
ng restricted panels of genes and studies focusing on microRNA
roﬁling, which employ distinct assays to proﬁle the “miRNAome”
ystem in blood leukocytes as well as in serum samples. Since
he unifying theme of this review is the transcriptome proﬁling of
hole blood the studies that proﬁled abundance of RNA in isolated
eukocyte populations were not recorded either. The ﬁnal step, after
he query results were curated, consisted in recording the cumula-
ive study counts for each subject matter at 4-year intervals starting
n 1998. Despite a genuine attempt at thoroughly surveying the lit-
rature some ﬁelds of investigation may  have been overlooked or
tudies missed. Therefore the results presented here are if anything
onservative estimates of the actual number of studies published
hat employed blood transcriptomics.
. Blood transcriptome proﬁling studies in health and
isease
Fig. 1 illustrates the evolution over time of the number of blood
ranscriptomic studies published across a wide range of subject
atters. The studies here are entirely restricted to work carried
ut with human subjects and not animals. In total 505 unique stud-
es were identiﬁed. Cumulative numbers of published articles are
eported for 2002, 2006, 2010 and 2014. Consistent color-coding
s used for different ﬁelds of investigations (e.g. darkest blue for
nfectious diseases, lime green for neurologic and psychiatric dis-
rders). Labels indicate in any given year the subjects matters,
rdered alphabetically along the x-axis, for which the number of
ublication reaches a count of 4, with the number of publications
eing plotted along the y-axis. Early adoption was observed in the
eld of autoimmunity, with Lupus, Rheumatoid Arthritis and Mul-
iple Sclerosis reaching this threshold in 2006 [9,20,21], and with
oth cancer and hepatitis research ﬁeld also contributing pioneer-
ng studies [22,23]. In 2010 study counts neared or surpassed 20
n all these research areas. This trend accelerated for Rheuma-
oid Arthritis and Multiple Sclerosis with counts nearing 40 in
014, but on the other hand stagnated for Lupus with only 3 new
tudies added between 2010 and 2014, with a count of 23 stud-
es to date. These differences can largely be attributed to the fact
hat investigations of Rheumatoid Arthritis and Multiple Sclerosis
hifted from examining changes associated with disease processes
o the investigation of mechanism of action of recently introduced
iological drugs and especially the identiﬁcation of markers pre-
icting response to therapy [24–27]. No such treatment modalities
re available to date for the treatment of patients with Lupus and
he few recent studies have for the most part focused instead on
atient stratiﬁcation [28–30]. The number of blood transcripto-
ic  studies investigating patients with hepatitis has also increased
teadily over recent years, reaching a count of 29 to date, with stud-
es reporting the characterization of interferon signatures in theunology 27 (2015) 58–66
blood of patients with hepatitis infection [31–33] and the identi-
ﬁcation of signatures associated with response to therapy [34,35].
But the largest increase has been in the number of publications uti-
lizing blood transcriptome proﬁling in the context of cancer studies.
Indeed, out of 57 studies to date 39 were published between 2010
and 2014 alone. This coincides with the mounting evidence over
recent years of the efﬁcacy of therapeutic strategies leveraging the
immune system as a means to treat cancer, and more generally of
the role played by the immune system in cancer pathogenesis [36].
Cancer studies have made use of blood transcriptomics for early
disease detection [37–39] as well as the investigation of patho-
genesis and therapeutic interventions [39–41]. Infectious diseases
have also been extensively studied starting after 2006. In 2010 the
number of sepsis studies reaches 18, starting from a count of only
one in 2006. HIV, Tuberculosis, Inﬂuenza and Malaria blood trans-
criptomic studies have also become prevalent after 2010 [42–50].
Overall the number of studies for the 6 infectious disease subject
matters surveyed reached 103 in 2014. It should be noted that space
limited the number of infectious diseases or conditions that could
ﬁt on this ﬁgure. Indeed a signiﬁcant number of studies pertain-
ing to other infectious diseases that are not listed here have also
been published, with for instance 11 articles to date on Dengue
infection alone (e.g. [51–53]) or 5 on Staphylococcus aureus infec-
tion (e.g. [54,55]). Notably considerable interest has also emerged
recently over the use of blood transcriptomic platforms for the
proﬁling of in vivo responses to vaccines (e.g. [10,56–60]). Global
changes in blood transcript abundance have also been investigated
in patients with cardiovascular diseases, including heart diseases
(e.g. atrial ﬁbrillation [61] and heart failure [62]), hypertension (e.g.
[63]) and stroke, with 21 studies published to date that have char-
acterized blood transcript signatures associated with stroke and
in some cases found to be predictive of recovery or complications
(e.g. [64–66]). Interest has soared in recent years over the use of
blood transcriptome proﬁling in studies involving patients with
neurological disorders. In Fig. 2 a total of 53 studies have been cat-
aloged in the Autism, Alzheimer or the broad “mental disorder”
category, with 30 of which being published in the last two  years
alone. Studies range between investigation of Autism (e.g. [67]), to
depression [68,69], anorexia [68], suicidality [70] or schizophrenia
[71]. The considerable interest in use of this approach in the study
of Alzheimer’s disease has been largely spurred by the prospect
of the development of a predictive blood transcriptomic diagnos-
tic test [72–74]. Another ﬁeld that has seen sustained interest and
the prospect of the development of non-invasive clinical assays is
transplantation medicine, with to date over 20 studies. These stud-
ies have investigated blood transcriptional signatures in subjects
receiving liver, kidney, heart, lung or bone marrow transplants,
with in this case the prospect of uncovering signatures that are
predictive of operational tolerance or rejection (e.g. [75–80]). The
effect of exposure to environmental factors, whether physical or
chemical, on blood transcriptome signatures has also been reported
in over 20 published studies (e.g. [81,82]), as have studies mea-
suring in the blood changes in transcript levels associated with
diabetes (e.g. [83–85]). Finally, investigative studies have also been
published but in smaller numbers that pertain to various subjects
matters ranging from respiratory diseases (16 studies, e.g. [86,87]),
exercise (16 studies, e.g. [88,89]), trauma (9 studies, e.g. [90,91]),
pregnancy (7 studies, e.g. [92–94]), allergy (6 studies, e.g. [95]). And
this list could clearly be made much longer.
5. Blood transcriptome proﬁling studies in various animals
species
Fig. 2 illustrates the evolution of the number of blood trans-
criptomic studies published for various animal species, including
D. Chaussabel / Seminars in Immunology 27 (2015) 58–66 61
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ere published investigating the blood transcriptome of cattle and
igs and two model animals, the rat and NHPs. Interestingly, it is
ot until 2010 that a signiﬁcant number of mouse studies are pub-
ished, but this trend is sustained through 2014 and the number of
ublished studies is now of 32, on par with the other “lead species”,
uch as the rat (41 studies), NHPs (40 studies), cows and pigs (33
nd 32 studies respectively). Mouse immunologists, who  tend to
avor organs such as the spleen, liver, lungs that are not readily
ccessible in human studies, do not commonly use blood. This fact
ay  explain the relatively slow adoption rate observed here. Exam-
ning the number of publications by species in 2014 (bottom right
anel) one can observe the gap that has formed between the “lead
pecies” and the rest. A potential explanation may  come from the
imited availability of commercial microarray platforms for species
ther than Rat, NHPs, cows, pigs and mice. Unequal distribution
f research funding is in all likelihood another contributing fac-
or. And while availability of RNA-sequencing technologies disrupts
he reliance on dedicated species-speciﬁc proﬁling array platforms,
he cost and relative complexity of this approach means that it
ay  take some time before the “lesser” animal species (on this
raph) begin to close this gap. But some species have started to
merge, with most notably the horse (13 studies in 2014), and at
resent at least ﬁve studies that have been published investigating
he blood transcriptome of dogs or dolphins. Interestingly some
hemes rapidly emerge when reviewing the blood transcriptomics
iterature for these different species. Indeed, rat studies are often
esigned to assess toxicity or pharmacological compounds or envi-
onmental factors (e.g. [96,97]), while studies in the pig or cow
isproportionately revolve around resistance to infection, in par-
icular Mycobacterium bovis in cattle and Salmonella in pigs (e.g.
98–100]). Reproductive biology studies are also well represented
e.g. [101–103]), which was in comparison a very minor theme in
uman studies. As can be expected these themes are common to
ost species of economical relevance. This is for instance the case of
tudies conducted in sheep and goats [104–106], as well as chicken
107] and ﬁsh [108].
Taken together this survey of the literature reveals the consider-
ble breadth of blood transcriptomic studies, both across diseases
nd species. While this development is remarkable in itself it also
ffers distinct opportunities for advancing novel strategies for the
xploitation of systems-scale proﬁling technologies. One oppor-
unity lies with the use of the contextual data provided by those
tudies for the mining and interpretation of individual datasets
s well as for the mining of large dataset collections. Having the
bility to use blood transcriptomics as a unifying theme in order
o bridge traditional research silos is in itself another signiﬁcant
pportunity, and would provide the means to exchange informa-
ion and methodologies and to coordinate future large-scale blood
ranscriptome proﬁling efforts.
. Meeting global health challenges
Blood transcriptomics has been widely employed in the study
f immune processes involved in health maintenance and disease
athogenesis in human studies. It has contributed valuable insights,
hich in some cases have translated into novel therapeutic modal-
ties [109], as well as diagnostic assays [72,110,111]. But successes
ave been few and far apart and blood transcriptomics studies have
een slow to yield information that can be leveraged by physicians
or clinical decision-making. Several factors may  be contributing
o this state of things. The current regulatory and intellectual pro-
ection environment is not favorable to the sustenance of business
entures, which have traditional been the means by which diag-
ostics tools are implemented and widely disseminated. Go or
o go decisions come down to assessing cost vs. beneﬁt. And atunology 27 (2015) 58–66
the moment there might just be too much risk to easily justify
the upfront investment necessary for validating and productizing
diagnostic assays, which results in poor prospects for translating
promising results into clinical assays. But the cost and beneﬁt bal-
ance might be shifted in low-income settings where disease burden
is high and access to medical facilities is limited. It is especially true
of course if beneﬁt is assessed not only from monetary but also from
a medical care standpoint.
Finding in cutting-edge molecular proﬁling technology the solu-
tion to medical challenges faced by destitute populations seems at
ﬁrst counterintuitive. The appeal of using systems approaches in
such settings primary lies in the fact that systems proﬁling assays
are by deﬁnition generic. Indeed, if everything that there is to be
measured is in fact measured by such assays, then there is no need
for arrays of dedicated kits or instruments for running different
diagnostic tests. It theoretically would make it possible to run a
comprehensive diagnostic lab with a single instrument running a
single assay. Indeed, as illustrated in this review measuring molec-
ular changes on a systems scale – in this case transcript abundance
in blood – can be relevant to a wide range of diseases and condi-
tions. It could potentially encompass infectious disease diagnosis
– which are of especially high burden in developing countries –
but also autoimmunity, cancer, neurological diseases, cardiovas-
cular diseases, nutrient deﬁciencies, pregnancy, etc. Furthermore
systems-scale proﬁling data have shown promise in enabling clini-
cal decision-making not only with respects to differential diagnosis
but also for the prediction of disease onset, or disease outcome,
as well as assessing disease severity and monitoring treatment
response [43].
But despite the very signiﬁcant upsides described above, costs
associated with running systems scale assays remains very signiﬁ-
cant. After all not only the instruments are expensive to purchase,
but the assays are also costly to run – not to mention the infrastruc-
ture necessary to house such instruments and IT/bioinformatics
overhead. Running such assays also requires extensive training.
Furthermore, in many clinical applications, and especially for infec-
tious diseases diagnostic, turnaround time is also critical, which
would preclude adopting a highly centralized model. And even
then, assay run time for systems -scale proﬁling assays tends to be
calculated in a matter of days rather than hours. Therefore, where
does the path forward lies for translating systems approaches into
diagnostic tools in such settings? Technological breakthroughs are
likely to bring the answer and shift this balance. This is illustrated by
the recently introduced Oxford Nanopore’s minION device, which
enables high throughput sequencing on an instrument the size of
a (large) thumb drive and that plugs directly into a computer’s
USB port [112]. The device is not reusable and costs about $1000
USD, furthermore suitability for clinical use in terms of robustness
or reproducibility is unknown, but the advent of such a technol-
ogy perfectly illustrates the fact that we may  only be one or two
technological breakthroughs removed from being able to imple-
ment systems approaches in settings where medical or laboratory
infrastructure is quasi inexistent. Thus the prospect of leapfrogging
the infrastructure-heavy western model for clinical diagnostic is
very real, and could parallel the remarkable technology-enabled
paradigm shift those countries have experienced, starting from no
communication infrastructure at all to the ubiquitous use of cel-
lular phones, without ever going through the intermediate step of
using ﬁxed phones connected to landlines.
If it is only a matter of time until such technology break-
through(s) materialize what can be done in the meantime? We
are in fact faced with a particularly tall order since technological
advances will be necessary but not sufﬁcient. Indeed, generating
the data might be the least challenging task when compared with
the extraction of reliable and actionable information from the vast
amounts of data generated from a systems-scale proﬁling assay.
D. Chaussabel / Seminars in Immunology 27 (2015) 58–66 63
Fig. 3. The dream: Enable Clinical Decision-Making with a Universal Proximity Testing Device. Technological breakthrough will enable rapid and cost-effective proximity
testing  via portable devices capable of running large-scale proﬁling assays (1). The data thus generated will be transferred wirelessly to a mobile communication device
such  as a smartphone or tablet. In turn the data will be transmitted to a remote server via cellular or satellite networks where it will be processed and run against extensive
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t means moving beyond the proof of principle, which is what
ost studies published to date have offered, and in a coordinated
ffort build platforms for the development and validation of refer-
nce databases and algorithms that starting from large scale data
ill provide clinicians with information they can use for clinical
ecision-making for an increasing catalog of indications. Data can
e generated on systems scales with technologies that are available
ow; granted that the practicality and price point is not as it should
e to allow adoption, but the data is essentially the same as what
hose “next next-generation” platforms would produce. Numerous
lood transcriptomics studies have already been conducted that
re of immediate relevance to populations in developing countries
42,44,51]. Currently the prevalent model, as can be expected, con-
ists in collecting blood samples at local sites in resource-limited
ountries to be run and the results analyzed in facilities in resource-
ich ones. But here I would make the case that there is also an
mportant need for building blood transcriptomic research capacity
ocally starting right now. I could come up with three main argu-
ents in favor of this, with the need to: (1) Build local immunology
esearch capabilities; ﬁrstly, there is, in my  probably biased opin-
on, an obvious immunology research gap to ﬁll. It is something I
ealized while visiting the Wellcome Trust-supported Oxford Uni-
ersity collaboration within the Ministry of Health, Government of
aos, Mahosot Hospital Microbiology Laboratory in Vientiane, the
apital of Laos. The facility is state-of-the-art according to west-
rn standards. But while the high infectious disease burden amply
ustify the clinical and research microbiology lab infrastructure, as
s illustrated by this review much can also be learned from pro-
ling host immune responses to pathogens, and the use of such
latform can extend well beyond the ﬁeld of infectious diseases.
ther similarly equipped facilities exist around the world and are
perated often through cooperation agreements between western
rganization and local authorities. The Pasteur institute’s exten-
ive international network is another such example. Building local
mmune proﬁling capacity also opens the prospects of building
nternational surveillance programs, in order to monitor emergent
nfectious diseases and outbreaks. Indeed, host immune responsesd back to the mobile device and actionable information will be presented to health
can be measured in the blood even when pathogens are not present
and provide valuable information with regards to severity of dis-
ease and response to antimicrobial therapy and is therefore highly
complementary to efforts focusing on direct pathogen detection.
Having local data acquisition capacity in place becomes especially
valuable in situations where outbreaks occur where pathogens
are highly infectious and samples cannot easily travel outside of
transmission areas, such as is the case with the 2014 Ebola epi-
demic. Here is my  second argument: (2) Find solutions adapted to
local unmet clinical needs; once capacity has been established for
research it can be brought to bear to address local unmet clinical
needs. Disease burden can vary considerably from one setting to
another. Host and environmental factors are also likely to have an
impact on blood transcriptional responses and biomarker develop-
ment may  require a “localized” – if not personalized – approach.
These factors include for instance genetic background, disease bur-
den (e.g. infestation with intestinal parasites), water quality or
nutrition. It can be thus anticipated that databases containing ref-
erence proﬁles would be constituted by locally recruited cases.
Weighting cost vs. beneﬁts is here again likely to be the means by
which the pace of translation of assay results in clinical decision-
making will be determined and it is an assessment that will also
need to be made locally on a case-by-case basis, based on the tools
and resources available to medical personnel locally at any given
point in time. Indeed, availability of adequate antibiotics supplies
may  for instance inﬂuence how a physician will treat information
regarding the likelihood of a respiratory infection to be of bacterial
or viral origin. (3) Prepare the ground for deployment of stream-
lined large-scale proﬁling technologies; thirdly, while the systems
proﬁling platforms are not yet ready for prime time for this type
of applications it is essential, taking technologies that are currently
available to us, to model “the dream” as closely as possible, and
to incorporate technological advances that will allow the minia-
turization of instruments and lowering costs to the point where
systems scale blood transcript proﬁling will be carried out using a
drop of blood captured by a portable device that will generate data
in a matter of minutes and relate the results to those available in a
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entral reference database through the use of wireless communi-
ation protocols (Fig. 3).
But how close are we really to becoming able to start build-
ng such research capacity in resource-constrained settings? In
he short term the answer may  lie in the use of streamlined
systems-like” approaches; or in other words targeted assays that
re underpinned by systems scale proﬁling approaches. During the
ourse of work carried out in various settings around the world
US, Spain, Macedonia, Thailand, Mexico, South Africa to name a
ew) our group generated blood transcriptome data from subjects
ith a wide range of diseases and conditions. From these and other
atasets we have built modular repertoires – which consists in the
dentiﬁcation of inter-dependencies amongst transcripts detected
n human whole blood. This entirely data-driven approach con-
ists of mapping relationships among group of genes on the basis
f co-clustering patterns across a multiple datasets. This mining
trategy has been described in detail in earlier publications and in
 review article [6,113]. For instance we have most recently built a
arge gene co-clustering network using as input 15 different blood
ranscriptome datasets encompassing whole genome proﬁles of
1000 subjects and spanning infectious and autoimmune diseases
s well as cancer. A total of 384 highly densely connected subnet-
orks of co-clustering genes, also called modules, were identiﬁed
nd can in turn serve as a stable framework for data analysis and
nterpretation of any blood transcriptome dataset. But the point
 want to make here is that this modular repertoire framework
an in turn be used to develop targeted assays; simply by select-
ng a few transcripts which expression patterns are representative
f that of the entire module (tens to hundreds of genes) [6]. It
hould be noted that this selection process is entirely data driven
nd informed by systems-scale proﬁling. The end result is a tar-
eted panel encompassing up to 270 transcripts (for 3 tiers) and
s few as 90 transcripts (for 1 tier). Such a targeted “transcrip-
ome ﬁngerprinting assay” – can be run on meso-scale proﬁling
latforms such as the Nanostring nCounter or Fluidigm Biomark
ystems. When run on a Fluidigm high throughput nanoliter-scale
CR system the reagent cost can be as low as $25/sample for one
ier, and results can be turned around in a matter of hours. Sample
rocessing workﬂow is straightforward as is the analytic pipeline,
nd web-based software applications are being implemented. This
bviously falls well short of the dream, given the reliance on a
elatively large and expensive instrument and the fact that while
he selection of the gene panel has been informed by systems
ata the assay remains targeted–and thus can only be qualiﬁed as
systems-like”. But the assay retains some important characteris-
ics of systems approaches, given for instance that it is designed
s a generic immune proﬁling assay that will detect perturba-
ions associated with a wide range of immune mediated-diseases.
t can thus be used for biomarker signature discovery, with the
dvantage of relying on PCR technology that is both sensitive and
asily translatable in point of care diagnostic using conventional
CR technology. Because it does not measure everything this assay
s less penalized by multiple testing corrections. This, combined
ith its higher sensitivity, can actually contribute to improve per-
ormances for biomarker signature discovery. This transcriptome
ngerprinting-based strategy has been successfully benchmarked
gainst a traditional microarray-based systems approach for the
iscovery of pre-symptomatic biomarkers with comparable per-
ormances obtained faster and at a much lower cost (manuscript in
reparation). The transcriptome ﬁngerprinting strategy and com-
anion software superﬁcially described here have been showcased
n a recent innovation article calling for the democratization of sys-
ems immunology approaches [6]. Indeed the intent is to make this
ssay and software toolkits available as an open source platform
nvestigators could add on and modify to ﬁt their own needs and
e-share for the beneﬁt of the community.unology 27 (2015) 58–66
Finally, it should also be noted that a very similar case could be
made for the use of systems, or initially systems-like, approaches
for veterinary medicine. As illustrated by the literature survey
described above the translation potential of blood transcriptome
proﬁling approaches has been demonstrated in animals of agri-
cultural relevance. In fact, the same technology platform and
translational research infrastructure deployed for the discovery
of biomarker signatures of human diseases could be shared for
that purpose. Notably integration of both human and veterinary
medicine translational research activities aligns with the emerg-
ing “one health” or “dual purpose with dual beneﬁts” concepts – to
both human and animal health [114,115].
Obviously blood transcriptomics does not by any means tell
the whole story. Other systems approaches will complete the
picture by providing information about the state of other compart-
ments such as the serum proteome and metabolome as well as the
gut microbiome, which taken together will contribute to clinical
decision-making. But proﬁling the blood transcriptome could be a
good starting point. Its appeal lies in the fact that it is simple and
that the level of maturity of the technologies it relies on is rela-
tively high. Success breeds success, and getting started along that
path would “only” take making a proof of principle for the use of a
unifying systems or “systems-like” approaches in low resource sett-
ings to address unmet clinical needs across a wide range of diseases
in humans and in economically relevant animal species.
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